Literature DB >> 8446273

Long-term cyclosporin A therapy for severe idiopathic membranous nephropathy.

G Rostoker1, D Belghiti, A Ben Maadi, P Rémy, P Lang, B Weil, G Lagrue.   

Abstract

Fifteen patients with nephrotic idiopathic membranous nephropathy (MN) with predictors of poor outcome were treated with a long cyclosporin A (CyA) regimen at the dose of 4-5 mg/kg/day for a median period of 15 months (range 12-30). Four of the 15 patients did not respond to CyA, and the therapy was discontinued after 4 months. A partial remission (proteinuria < 2 g/day) was observed in 7 of 15 patients and a complete remission (proteinuria < 0.2 g/day) in 4 of 15 patients; good results (partial+complete remission) were, thus, obtained in 11 of 15 patients (73%). Two patients are still receiving therapy. A relapse of the nephrotic syndrome occurred in 3 of 9 patients on withdrawal of CyA, but the relapse remained sensitive to CyA. Side effects were mild. We conclude that CyA may be efficient in the treatment of MN and should be evaluated in controlled trials.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8446273     DOI: 10.1159/000187219

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  10 in total

1.  Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment.

Authors:  Melahat Coban; Remziye Nur Eke; Filiz Kizilates; Secil Ucar; Fatih Dede
Journal:  Int J Clin Exp Med       Date:  2014-01-15

Review 2.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 4.  Controversies in the treatment of idiopathic membranous nephropathy.

Authors:  Meryl Waldman; Howard A Austin
Journal:  Nat Rev Nephrol       Date:  2009-07-07       Impact factor: 28.314

Review 5.  Treatment of idiopathic membranous nephropathy.

Authors:  Meryl Waldman; Howard A Austin
Journal:  J Am Soc Nephrol       Date:  2012-08-02       Impact factor: 10.121

6.  Inducible ATF3-NFAT axis aggravates podocyte injury.

Authors:  Hong Zhang; Shun Liang; Yue Du; Ruizhao Li; Chaosheng He; Wenjian Wang; Shuangxin Liu; Zhiming Ye; Xinling Liang; Wei Shi; Bin Zhang
Journal:  J Mol Med (Berl)       Date:  2017-10-16       Impact factor: 4.599

7.  The Unpredictability of Idiopathic Membranous Nephropathy: An Illustrative Case Report.

Authors:  Murray L Levin; Shubhada Ahya
Journal:  Case Rep Nephrol Dial       Date:  2018-06-01

Review 8.  Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.

Authors:  Francesco Scolari; Federico Alberici; Federica Mescia; Elisa Delbarba; Hernando Trujillo; Manuel Praga; Claudio Ponticelli
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561

9.  Chapter 7: Idiopathic membranous nephropathy.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-06

10.  Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial.

Authors:  Takao Saito; Masayuki Iwano; Koichi Matsumoto; Tetsuya Mitarai; Hitoshi Yokoyama; Noriaki Yorioka; Shinichi Nishi; Ashio Yoshimura; Hiroshi Sato; Satoru Ogahara; Hideki Shuto; Yasufumi Kataoka; Shiro Ueda; Akio Koyama; Shoichi Maruyama; Masaomi Nangaku; Enyu Imai; Seiichi Matsuo; Yasuhiko Tomino
Journal:  Clin Exp Nephrol       Date:  2013-12-23       Impact factor: 2.801

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.